SURVIVORSHIP PROGRAM: SECOND MALIGNANCIES IN LYMPHOMA SURVIVORS
(Abstract release date: 05/19/16)
EHA Library. Simula M. 06/09/16; 134754; PB1854
Dr. Maria Pina Simula
Contributions
Contributions
Abstract
Abstract: PB1854
Type: Publication Only
Background
Improvements in the treatment of both Hodgkin’s (HL) and non Hodgkin’s Lymphomas (nHL) have resulted in an increasing number of long term survivors. However this patient’s population is at high risk of developing late therapy related complications that can negatively affect long term survival and quality of life.
Aims
In our institution the HL and aggressive NHL long term survivors are followed up in a dedicated clinic since September 2014. Here we report preliminary data on second malignancies.
Methods
We have collected retrospective data on second tumours in 469 consecutive lymphoma survivors.
Results
We have analyzed data regarding 469 patients coming in our clinic from 15 September 2014 to 18 February 2016, 247 have been successfully treated for HL and 222 for nHL. Two hundred thirty three were females, 236 males; median of age at lymphoma diagnosis was 29 years for HL (range 13-84) and 48 years for nHL (range 12-83). Median age at last observation in the follow up clinic was 50 years for HL (range 21-89) and 62 years for nHL (range 24-88).The median of duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL (range 5-37).Sixty two patients (13%) experienced a second cancer, 4 of them had 2 neoplasms, so we documented 66 second tumours (Table 1). They were: 23 skin (35%) and 43 non cutaneous cancers (65%).The non skin neoplasms were: 10 breast, 9 gastroenteric, 8 thyroid, 6 prostatic, 1 lung, 4 bladder, 1 renal, 1 tongue, 1 testis 1 gynecological metastatic, and 1 cutaneous appendages malignant cancers (Table 2). Four of these tumours (2 colon, 1 thyroid and the metastatic gynecological one) have been diagnosed with our program of early diagnosis of second cancers and thyroid dysfunctions.The median of time between diagnosis of lymphoma and diagnosis of second malignancy was 18 years (range 1-41).Regarding the previous therapies: mediastinal radiotherapy has been administered to 7 out of 10 of the females with breast cancer (70%), mantel or neck radiotherapy to 6 out of 8 (75%) with thyroid cancer; no one of the intestinal and prostatic cancers have received abdominal radiotherapy; one out of 4 of the patients with urinary cancer (25%) had abdominal radiotherapy and MOPP/ABVD regimen; the one with lung cancer had MOPP chemotherapy and mantle radiotherapyChemotherapy has been administered for the treatment of lymphoma to 6 with breast (60%), to 7 with thyroid (88%), to all with gastroenteric (100%), and to 4 with bladder cancers (67%).Median of age of breast cancer in our setting was 50 years (range 38-70), of thyroid cancer was 40.5 years (range 24-55), and of gastroenteric cancer was 66 years (range 42-83).Moreover we have documented relapse of their original lymphoma in 3 patients (2 HL and 1 nHL) respectively at 9, 22 and 28 years after initial diagnosis.
Conclusion
In our Department we described a significant number of cases of second neoplasms in the lymphoma survivors population: 4 of these (9% of non cutaneous cancers) were detected by tests done for early diagnosis of late complications. These results outlne the importance of a risk adapted plan for early diagnosis of cancers in this setting of patients that would be encouraged by both hematologist and general practitioners.
Session topic: E-poster
Keyword(s): Cancer, Lymphoma
Type: Publication Only
Background
Improvements in the treatment of both Hodgkin’s (HL) and non Hodgkin’s Lymphomas (nHL) have resulted in an increasing number of long term survivors. However this patient’s population is at high risk of developing late therapy related complications that can negatively affect long term survival and quality of life.
Aims
In our institution the HL and aggressive NHL long term survivors are followed up in a dedicated clinic since September 2014. Here we report preliminary data on second malignancies.
Methods
We have collected retrospective data on second tumours in 469 consecutive lymphoma survivors.
Results
We have analyzed data regarding 469 patients coming in our clinic from 15 September 2014 to 18 February 2016, 247 have been successfully treated for HL and 222 for nHL. Two hundred thirty three were females, 236 males; median of age at lymphoma diagnosis was 29 years for HL (range 13-84) and 48 years for nHL (range 12-83). Median age at last observation in the follow up clinic was 50 years for HL (range 21-89) and 62 years for nHL (range 24-88).The median of duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL (range 5-37).Sixty two patients (13%) experienced a second cancer, 4 of them had 2 neoplasms, so we documented 66 second tumours (Table 1). They were: 23 skin (35%) and 43 non cutaneous cancers (65%).The non skin neoplasms were: 10 breast, 9 gastroenteric, 8 thyroid, 6 prostatic, 1 lung, 4 bladder, 1 renal, 1 tongue, 1 testis 1 gynecological metastatic, and 1 cutaneous appendages malignant cancers (Table 2). Four of these tumours (2 colon, 1 thyroid and the metastatic gynecological one) have been diagnosed with our program of early diagnosis of second cancers and thyroid dysfunctions.The median of time between diagnosis of lymphoma and diagnosis of second malignancy was 18 years (range 1-41).Regarding the previous therapies: mediastinal radiotherapy has been administered to 7 out of 10 of the females with breast cancer (70%), mantel or neck radiotherapy to 6 out of 8 (75%) with thyroid cancer; no one of the intestinal and prostatic cancers have received abdominal radiotherapy; one out of 4 of the patients with urinary cancer (25%) had abdominal radiotherapy and MOPP/ABVD regimen; the one with lung cancer had MOPP chemotherapy and mantle radiotherapyChemotherapy has been administered for the treatment of lymphoma to 6 with breast (60%), to 7 with thyroid (88%), to all with gastroenteric (100%), and to 4 with bladder cancers (67%).Median of age of breast cancer in our setting was 50 years (range 38-70), of thyroid cancer was 40.5 years (range 24-55), and of gastroenteric cancer was 66 years (range 42-83).Moreover we have documented relapse of their original lymphoma in 3 patients (2 HL and 1 nHL) respectively at 9, 22 and 28 years after initial diagnosis.
Conclusion
In our Department we described a significant number of cases of second neoplasms in the lymphoma survivors population: 4 of these (9% of non cutaneous cancers) were detected by tests done for early diagnosis of late complications. These results outlne the importance of a risk adapted plan for early diagnosis of cancers in this setting of patients that would be encouraged by both hematologist and general practitioners.
Session topic: E-poster
Keyword(s): Cancer, Lymphoma
Abstract: PB1854
Type: Publication Only
Background
Improvements in the treatment of both Hodgkin’s (HL) and non Hodgkin’s Lymphomas (nHL) have resulted in an increasing number of long term survivors. However this patient’s population is at high risk of developing late therapy related complications that can negatively affect long term survival and quality of life.
Aims
In our institution the HL and aggressive NHL long term survivors are followed up in a dedicated clinic since September 2014. Here we report preliminary data on second malignancies.
Methods
We have collected retrospective data on second tumours in 469 consecutive lymphoma survivors.
Results
We have analyzed data regarding 469 patients coming in our clinic from 15 September 2014 to 18 February 2016, 247 have been successfully treated for HL and 222 for nHL. Two hundred thirty three were females, 236 males; median of age at lymphoma diagnosis was 29 years for HL (range 13-84) and 48 years for nHL (range 12-83). Median age at last observation in the follow up clinic was 50 years for HL (range 21-89) and 62 years for nHL (range 24-88).The median of duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL (range 5-37).Sixty two patients (13%) experienced a second cancer, 4 of them had 2 neoplasms, so we documented 66 second tumours (Table 1). They were: 23 skin (35%) and 43 non cutaneous cancers (65%).The non skin neoplasms were: 10 breast, 9 gastroenteric, 8 thyroid, 6 prostatic, 1 lung, 4 bladder, 1 renal, 1 tongue, 1 testis 1 gynecological metastatic, and 1 cutaneous appendages malignant cancers (Table 2). Four of these tumours (2 colon, 1 thyroid and the metastatic gynecological one) have been diagnosed with our program of early diagnosis of second cancers and thyroid dysfunctions.The median of time between diagnosis of lymphoma and diagnosis of second malignancy was 18 years (range 1-41).Regarding the previous therapies: mediastinal radiotherapy has been administered to 7 out of 10 of the females with breast cancer (70%), mantel or neck radiotherapy to 6 out of 8 (75%) with thyroid cancer; no one of the intestinal and prostatic cancers have received abdominal radiotherapy; one out of 4 of the patients with urinary cancer (25%) had abdominal radiotherapy and MOPP/ABVD regimen; the one with lung cancer had MOPP chemotherapy and mantle radiotherapyChemotherapy has been administered for the treatment of lymphoma to 6 with breast (60%), to 7 with thyroid (88%), to all with gastroenteric (100%), and to 4 with bladder cancers (67%).Median of age of breast cancer in our setting was 50 years (range 38-70), of thyroid cancer was 40.5 years (range 24-55), and of gastroenteric cancer was 66 years (range 42-83).Moreover we have documented relapse of their original lymphoma in 3 patients (2 HL and 1 nHL) respectively at 9, 22 and 28 years after initial diagnosis.
Conclusion
In our Department we described a significant number of cases of second neoplasms in the lymphoma survivors population: 4 of these (9% of non cutaneous cancers) were detected by tests done for early diagnosis of late complications. These results outlne the importance of a risk adapted plan for early diagnosis of cancers in this setting of patients that would be encouraged by both hematologist and general practitioners.
Session topic: E-poster
Keyword(s): Cancer, Lymphoma
Type: Publication Only
Background
Improvements in the treatment of both Hodgkin’s (HL) and non Hodgkin’s Lymphomas (nHL) have resulted in an increasing number of long term survivors. However this patient’s population is at high risk of developing late therapy related complications that can negatively affect long term survival and quality of life.
Aims
In our institution the HL and aggressive NHL long term survivors are followed up in a dedicated clinic since September 2014. Here we report preliminary data on second malignancies.
Methods
We have collected retrospective data on second tumours in 469 consecutive lymphoma survivors.
Results
We have analyzed data regarding 469 patients coming in our clinic from 15 September 2014 to 18 February 2016, 247 have been successfully treated for HL and 222 for nHL. Two hundred thirty three were females, 236 males; median of age at lymphoma diagnosis was 29 years for HL (range 13-84) and 48 years for nHL (range 12-83). Median age at last observation in the follow up clinic was 50 years for HL (range 21-89) and 62 years for nHL (range 24-88).The median of duration of follow up was 18 years for HL (range 5-40) and 13 years for nHL (range 5-37).Sixty two patients (13%) experienced a second cancer, 4 of them had 2 neoplasms, so we documented 66 second tumours (Table 1). They were: 23 skin (35%) and 43 non cutaneous cancers (65%).The non skin neoplasms were: 10 breast, 9 gastroenteric, 8 thyroid, 6 prostatic, 1 lung, 4 bladder, 1 renal, 1 tongue, 1 testis 1 gynecological metastatic, and 1 cutaneous appendages malignant cancers (Table 2). Four of these tumours (2 colon, 1 thyroid and the metastatic gynecological one) have been diagnosed with our program of early diagnosis of second cancers and thyroid dysfunctions.The median of time between diagnosis of lymphoma and diagnosis of second malignancy was 18 years (range 1-41).Regarding the previous therapies: mediastinal radiotherapy has been administered to 7 out of 10 of the females with breast cancer (70%), mantel or neck radiotherapy to 6 out of 8 (75%) with thyroid cancer; no one of the intestinal and prostatic cancers have received abdominal radiotherapy; one out of 4 of the patients with urinary cancer (25%) had abdominal radiotherapy and MOPP/ABVD regimen; the one with lung cancer had MOPP chemotherapy and mantle radiotherapyChemotherapy has been administered for the treatment of lymphoma to 6 with breast (60%), to 7 with thyroid (88%), to all with gastroenteric (100%), and to 4 with bladder cancers (67%).Median of age of breast cancer in our setting was 50 years (range 38-70), of thyroid cancer was 40.5 years (range 24-55), and of gastroenteric cancer was 66 years (range 42-83).Moreover we have documented relapse of their original lymphoma in 3 patients (2 HL and 1 nHL) respectively at 9, 22 and 28 years after initial diagnosis.
Conclusion
In our Department we described a significant number of cases of second neoplasms in the lymphoma survivors population: 4 of these (9% of non cutaneous cancers) were detected by tests done for early diagnosis of late complications. These results outlne the importance of a risk adapted plan for early diagnosis of cancers in this setting of patients that would be encouraged by both hematologist and general practitioners.
Session topic: E-poster
Keyword(s): Cancer, Lymphoma
{{ help_message }}
{{filter}}